NS5B is the RNA-dependent RNA polymerase that catalyzes the replication of the hepatitis C virus genome. It is a major target for antiviral drugs including nucleoside analogs, such as the prodrugs mericitabine and sofosbuvir, which get metabolized to 2′-fluoro-2′C-methylcytidine-5′-triphosphate and 2′-fluoro-2′C-methyluridine-5′-triphosphate, respectively. These analogs act as chain terminators after they are incorporated during RNA synthesis. Recently, it has been shown that NS5B can efficiently remove chain terminators by a nucleotide-mediated excision reaction that rescues RNA synthesis. In this study, we use transient-state kinetics to understand the efficiency of inhibition of five nucleoside analogs. We show that CTP analogs are readily incorporated into a growing primer by NS5B but are also efficiently excised. In contrast, although UMP analogs are more slowly incorporated, the excision of UMP is slow and inefficient, and modifications to the 2′-carbon of the UTP ribose ring further decreased rates of excision to an undetectable level. Taken together, these data suggest that the clinical effectiveness of sofosbuvir is largely a function of being intrinsically resistant to nucleotide-mediated excision compared with similar nucleoside analogs.

The hepatitis C virus (HCV) infects an estimated 3% of the world’s population, with ~2.4 million people in the United States currently infected (1, 2). Chronic HCV infections lead to hepatic fibrosis, cirrhosis, and hepatocellular carcinoma (3). HCV is a plus-sense single-stranded RNA virus containing a 9.6-kb genome, which encodes a single polyprotein (4). This polyprotein consists of three structural proteins and seven non-structural proteins, including NS5B, the RNA-dependent RNA polymerase responsible for replicating the viral genome. NS5B catalyzes de novo initiation of RNA synthesis, which is inefficient in vitro but is followed by a transition to an efficient and fast processive elongation phase (5, 6).

NS5B is the target for many antiviral therapies including nucleoside analogs (7–9). These analogs work by mimicking the natural nucleotides and are incorporated during processive replication of the viral genome (10). Once incorporated, the analogs act as chain terminators by hindering polymerization of the next incoming base to prevent further elongation of the nascent RNA strand (11). These analogs include the prodrugs mericitabine and sofosbuvir, which get metabolized to 2′-fluoro-2′C-methylcytidine-5′-triphosphate and 2′-fluoro-2′C-methyluridine-5′-triphosphate, respectively (7, 12, 13).

Recent advancements have afforded formation and isolation of a processive elongation complex of NS5B with RNA in vitro (5). Transient-state kinetic methods have uncovered an efficient ATP-mediated excision reaction, which may play a role in maintaining fidelity during genome replication (14). Interestingly, ATP-mediated excision can also efficiently remove chain terminators, thereby rescuing RNA synthesis. This mechanism was also observed in AZT-resistant variants of HIV RT and is thought to be the main cause of AZT resistance (15–18). However, WT NS5B has been shown to be ~50-fold more efficient than AZT-resistant forms of HIV RT in removing chain terminators via ATP-mediated excision (14). This raises questions regarding how any chain-terminating nucleoside analog could be effective in treating HCV infections.

In this study, we use transient-state kinetic methods to measure the efficiencies of incorporation and excision of several nucleoside analogs (Fig. 1). We show that CTP and CTP analogs are efficiently incorporated but are also readily excised. Furthermore, although there is a large discrimination against incorporation of the 2′-modified UTP analog compared with unmodified UTP, ATP-dependent excision and pyrophosphorylation of UTP and its analog are very inefficient.

**Results**

**Incorporation of NTP and NTP analogs**

Analysis of the kinetics of nucleotide incorporation under single-turnover conditions afforded the apparent equilibrium dissociation constants for ground-state binding (K_{d,app}) and the rate constants for the maximum rate of incorporation (k_{pol}) for CTP and UTP. Although the rates of incorporation of CTP and UTP were sufficiently fast to require the use of rapid-quench-flow methods, the rates of incorporation of the analogs were slow, so the kinetics could be measured using hand-mixing methods. The reactions were measured under single-turnover conditions since the NS5B/9-nt/20-nt elongation complex pauses after the first incorporation because of the absence of the next complementary NTP and the dissociation of RNA from the enzyme is exceedingly slow (5). These measurements afforded the specificity constant (k_{cat}/K_{m} = k_{pol}/K_{d,app}). The
discrimination against incorporation of each analog was defined by the ratio of the specificity constant for the canonical nucleotide divided by that for the corresponding analog. The results for incorporation of CTP and CTP analogs (Fig. 2, A–D) and UTP and the UTP analog (Fig. 3, A and B) were fit based on Scheme 1 using KinTek Explorer software (Austin, TX). The results are summarized in Table 1. The kinetic parameters for incorporation of CTP \( (k_{\text{pol}} = 21 \pm 3 \, \text{s}^{-1}, K_{\text{d,app}} = 46 \pm 9 \, \mu\text{M}, k_{\text{pol}}/K_{\text{d,app}} = 0.46 \pm 0.1 \, \mu\text{M}^{-1} \, \text{s}^{-1}) \) are in agreement with previously reported results under similar conditions (5). The \( K_{\text{d,app}} \) for 2'C-Me-2'-F-CTP (59 ± 14 \, \mu\text{M}), 2'C-Me-CTP (61 ± 11 \, \mu\text{M}), and 4'-azido-CTP (23 ± 7 \, \mu\text{M}) were similar to that of CTP. However, the rate constant for incorporation for each of the three CTP analogs (1.9 ± 0.4, 1.0 ± 0.2, and 1.5 ± 0.4 \, \text{s}^{-1}) was significantly lower than for unmodified CTP.

The \( k_{\text{pol}} \) and \( K_{\text{d,app}} \) for UTP incorporation were 33 ± 5 \, \text{s}^{-1} and 320 ± 60 \, \mu\text{M}, respectively, giving a \( k_{\text{pol}}/K_{\text{d,app}} \) of 0.1 ± 0.02 \, \mu\text{M}^{-1} \, \text{s}^{-1}. Similar to the case with the CTP analogs, the \( K_{\text{d,app}} \) for incorporation of 2'C-Me-2'-F-UTP (410 ± 50 \, \mu\text{M}) was comparable with that for UTP. The maximum rate for incorporation of the UTP analog was 0.3 ± 0.03 \, \text{s}^{-1}, roughly 100-fold lower than the rate constant for incorporation of UTP so that \( k_{\text{pol}}/K_{\text{d,app}} = 0.0007 \pm 0.0001 \, \mu\text{M}^{-1} \, \text{s}^{-1} \). The enzyme discriminates against incorporation of 2'C-Me-2'-F-UTP by a factor 140 ± 45 relative to UTP. These results differ from previously published results for incorporation of the UTP analog (20), where the reported \( K_{\text{d,app}} = 113 \, \mu\text{M}, k_{\text{pol}} = 0.67 \, \text{s}^{-1}, \) and \( k_{\text{pol}}/K_{\text{d,app}} = 0.0059 \, \mu\text{M}^{-1} \, \text{s}^{-1} \) were ~8-fold more efficient compared with our measurements. This may be due to a difference in the strain used, as well as a difference in the sequence of the RNA template. Nevertheless, both results reflect a large discrimination against incorporation of the analog.

Our results reveal that the modifications of the ribose ring do not influence the apparent binding affinity of the analog; rather, discrimination against these analogs is driven by reduced values of \( k_{\text{pol}} \). All nucleoside analogs tested were shown to be effective chain terminators except for 4'-azido-CTP (data not shown). Therefore, the rest of this study focuses on the 2'C-modified nucleoside analogs.

Pyrophosphorolysis of incorporated NMPs and 2'C-modified NMP analogs

To examine the kinetics of excision by pyrophosphorolysis, the NS5B elongation complex was generated in the presence of either the unmodified nucleotide or the 2'C-modified analog to generate an NS5B/10-nt/20-nt enzyme/primer/template complex. We then mixed the complex with 0–2 mM sodium pyrophosphate supplemented with a 1:1 ratio of MgCl_2/pyrophosphate. The results were fit using Scheme 1, where \( K_3 \) is the apparent equilibrium dissociation constant for pyrophosphate, \( k_{-2} \) is the rate constant for pyrophosphorolysis, and \( k_{-2}/K_3 \) is the specificity constant for pyrophosphorolysis. The results are summarized in Table 2.

The rate constant for pyrophosphorolysis of CMP-terminated RNA \( (k_{-2}) \) was measured to be 0.3 ± 0.03 \, \text{s}^{-1}, and \( K_3 \) was determined to be 410 ± 50 \, \mu\text{M}, resulting in a specificity constant of \( (7.3 ± 1) \times 10^{-4} \, \mu\text{M}^{-1} \, \text{s}^{-1} \) (Fig. 4A). These results are well within range of previously reported results (14). The
rate constants for pyrophosphorolysis for 2’C-Me-CMP (Fig. 4B) and 2’C-Me-2’F-CMP (Fig. 4C) are 0.4 ± 0.04 s⁻¹ and 0.3 ± 0.03 s⁻¹, respectively. These rate constants are comparable to the rate constant for pyrophosphorolysis of CMP. There is a larger difference in the binding of pyrophosphate during excision of the analogs (820 ± 100 μM for 2’C-Me-CMP and 1600 ±
200 μM for 2’C-Me-2’F-CMP) when compared with CMP (410 ± 50 μM). These data indicate that binding of pyrophosphate, instead of the rate constant for excision, accounts for the difference in the specificity constant for pyrophosphorolysis.

According to our results, NS5B catalyzes pyrophosphorolysis of CMP more efficiently than 2’C-Me-CMP (k_{2}/K_{3}) for CMP is (7.3 ± 1) × 10^{-4} μM^{-1} s^{-1} versus (4.6 ± 0.8) × 10^{-4} μM^{-1} s^{-1}). 2’C-Me-2’F-CMP is most resistant to pyrophosphorolysis (k_{2}/K_{3} = (1.8 ± 0.2) × 10^{-4} μM^{-1} s^{-1}) compared with CMP and 2’C-Me-CMP. It is important to note that the apparent equilibrium constant for pyrophosphate binding will include a term for translocation of the RNA from the nucleotide-binding site to the primer-binding site. A more favorable equilibrium constant for translocation will reduce the apparent affinity for pyrophosphate binding. Thus, 2’C-modified nucleoside analogs may shift the translocation to move the 3’ nucleotide of the RNA away from the reaction center.

Our data demonstrate that the 2’F modification further increases resistance to excision via pyrophosphorolysis. We also noted that the amplitude of the observed reaction depended on pyrophosphate concentration, indicating that the reaction came to equilibrium such that the net reaction was linked to concentration of added pyrophosphate. This could be due to slow release or rebinding of the NTP product of the reaction. We fit the data according to Scheme 1 by allowing the rebinding and reincorporation of the NTP to afford estimates of k_{3} and the apparent equilibrium constant for NTP rebinding (K_{i}) to yield the specificity constant, k_{3}/k_{2}. The measured specificity constant for NTP reincorporation is nearly identical to the results from the nucleotide incorporation data. For this reason, we globally fit data for the kinetics of incorporation and pyrophosphorolysis to obtain the values for rate constants listed in Table 2.

UMP undergoes pyrophosphorolysis significantly less efficiently (see Fig. 6A) compared with CMP and the CMP analogs. The rate constant for pyrophosphorolysis was measured to be 0.007 ± 0.002 s^{-1}, and the apparent affinity for pyrophosphate binding was 1700 ± 200 μM. This slower rate constant and weaker binding results in a specificity constant of (0.041 ± 0.02) × 10^{-4} μM^{-1} s^{-1}, ~178-fold less than the k_{2}/K_{3} for pyrophosphorolysis of CMP. As with the pyrophosphorolysis of CMP and CMP analogs, an amplitude dependence was observed with increasing concentration of pyrophosphate due to the reincorporation of UTP. Under these conditions, k_{2} and K_{3} are almost identical to the results measured during the UTP incorporation reaction and so we globally fit with data for kinetics of incorporation and pyrophosphorolysis to obtain the values for rate constants listed in Table 2.

We attempted to measure the pyrophosphorolysis of 2’C-Me-2’F-UMP (see Fig. 7A). No pyrophosphorolysis was observed at any pyrophosphate concentration over the time course measured. To set an upper limit on the rate constant for pyrophosphorolysis, we estimate that within the limits of detection, <1% of the input substrate reacted at the highest concentration of pyrophosphate. Accordingly, we set an upper limit of k_{2}/K_{3} ≤ 0.0001 × 10^{-4} μM^{-1} s^{-1}. Together, these results indicate that efficiency of pyrophosphorolysis depends on the base, and modifications to the 2’-carbon on the ribose ring further increase resistance to pyrophosphorolysis.

**ATP-mediated excision of NMP and 2’C-modified NMP analogs**

We measured the efficiency of ATP-mediated excision by generating the NS5B/10-nt/20-nt elongation complex as described under "Materials and methods." We then incubated the complex with 0–8 mM ATP supplemented with a 1:1 molar ratio of MgCl2/ATP. The results were fit using Scheme 2, where k_{5} is the rate constant for ATP-mediated excision, 1/K_{4} is the apparent equilibrium dissociation constant for binding ATP during excision, and K_{6} is the specificity constant for ATP-mediated excision. We observed an ATP concentration dependence on the amplitude of the excision reaction, implying a reversible link between ATP binding and the equilibrium end point of the reaction. We account for the amplitude dependence by including the reverse reaction. In other words, the dinucleoside tetraphosphate (Ap_{4}N) product generated during the excision reaction can be reincorporated into the primer strand so the excision reaction comes to equilibrium. The rate constant for Ap_{4}N reincorporation is defined by k_{6}, the apparent equilibrium dissociation constant is K_{6}, and k_{5}/K_{6} defines the specificity constant for reincorporation. Although the apparent K_{6} and maximum rate of the reaction of Ap_{4}N are not defined, the data provide reasonable limits on the estimate of the specificity constant for reaction of Ap_{4}N, k_{5}/K_{6}. The results are summarized in Table 3.

The kinetic parameters for ATP-mediated excision of CMP (Fig. 5A) were comparable to previously published results (k_{5} = 0.043 ± 0.006 s^{-1}, 1/K_{4} = 2.8 ± 0.4 μM, K_{5}k_{5} = (1.5 ± 0.3) × 10^{-5} μM^{-1} s^{-1}). The incorporated CTP analogs were excised at slightly slower rates (k_{5} = 0.034 ± 0.002 s^{-1} and 0.024 ± 0.002 s^{-1} for 2’C-Me-CMP and 2’C-Me-2’F-CMP, respectively) when compared with excision of CMP. NS5B has a slightly higher apparent affinity for ATP during excision of 2’C-Me-CMP (1.6 ± 0.67 mM; Fig. 5B), but the apparent affinity remains relatively unchanged during excision of
**EDITORS’ PICK: Mechanism of NS5B inhibition by nucleotide analogs**

**Table 2**

**HCV NS5B nucleoside and nucleoside analog pyrophosphorolysis parameters**

Shown is a summary of kinetic parameters for pyrophosphorolysis of incorporated nucleosides and nucleoside analogs. The rate constants were derived by fitting the data sets using Scheme 1. S.E. values were derived by nonlinear regression in globally fitting the data (19). Confidence contour analysis supported the use of S.E. estimates derived from nonlinear regression.

<table>
<thead>
<tr>
<th>Nucleotide</th>
<th>$1/K_1$</th>
<th>$k_2$</th>
<th>$K_1 k_2$</th>
<th>$k_{-2}$</th>
<th>$K_3$</th>
<th>$k_{-2}/K_3 \times 10^6$</th>
</tr>
</thead>
<tbody>
<tr>
<td>CTP</td>
<td>46 ± 4</td>
<td>0.046 ± 0.005</td>
<td>15 ± 3</td>
<td>0.38 ± 0.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2'C-Me-CTP</td>
<td>54 ± 7</td>
<td>0.032 ± 0.006</td>
<td>20 ± 1</td>
<td>0.47 ± 0.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2'C-Me-2'F-CTP</td>
<td>56 ± 7</td>
<td>0.031 ± 0.006</td>
<td>12 ± 1</td>
<td>0.92 ± 0.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UTP</td>
<td>310 ± 70</td>
<td>0.09 ± 0.02</td>
<td>0.007 ± 0.002</td>
<td>1700 ± 200</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2'C-Me-2'F-UMP</td>
<td>410°</td>
<td>0.3°</td>
<td>0.0007°</td>
<td>0.01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Rate constants for 2'C-Me-2'F-UMP incorporation are from Table 2.*

**Figure 4. Pyrophosphorolysis of CMP and 2'C Modified CTP analogues.** The plots show the pyrophosphorolysis of CMP (31.25, 62.5, 125, 500, and 1000 μM) (A), 2'C-Me-CP (15.6, 31.3, 62.5, 125, 250, and 500 μM) (B) and 2'C-Me-2'F-CP (15.6, 31.3, 62.5, 125, 250, and 500 μM) (C). The data were fit using Scheme 2 using KinTek Explorer. Solid lines represent best fit resulting from the fitting process. Results are summarized in Table 2.

E$\cdot R_{10} +$ ATP $\xrightarrow{k_1} E \cdot R_{10} \cdot$ ATP $\xrightarrow{k_2} E \cdot R_9 \cdot$ Ap$_4$N $\xrightarrow{k_4} E \cdot R_9 +$ Ap$_4$N

**Scheme 2. Minimal model for ATP-mediated excision of incorporated nucleoside monophosphate.**

**Table 3**

**HCV NS5B nucleoside and nucleoside analog ATP-mediated excision**

Shown is a summary of kinetic parameters for ATP-mediated excision of incorporated nucleosides and nucleoside analogs. The rate constants were derived by fitting the data sets using Scheme 2. S.E. values were derived by nonlinear regression in globally fitting the data (19). The individual rates for the reverse reactions are not defined by the data, and therefore only the specificity constant ($k_{-2}/K_3$) is able to be determined.

<table>
<thead>
<tr>
<th>Nucleotide</th>
<th>$1/K_4$</th>
<th>$k_5$</th>
<th>$K_4 k_5 \times 10^{-6}$</th>
<th>$k_{-2}/K_3$</th>
</tr>
</thead>
<tbody>
<tr>
<td>CMP</td>
<td>2800 ± 400</td>
<td>0.043 ± 0.006</td>
<td>15 ± 3</td>
<td>0.38 ± 0.2</td>
</tr>
<tr>
<td>2'C-Me-CMP</td>
<td>1600 ± 67</td>
<td>0.034 ± 0.002</td>
<td>20 ± 1</td>
<td>0.47 ± 0.2</td>
</tr>
<tr>
<td>2'C-Me-2'F-CMP</td>
<td>2100 ± 100</td>
<td>0.024 ± 0.002</td>
<td>12 ± 1</td>
<td>0.92 ± 0.3</td>
</tr>
<tr>
<td>UMP</td>
<td>0.05 ± 0.02</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2'C-Me-2'F-UMP</td>
<td>≤0.004</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2'C-Me-2'F-CMP (2.1 ± 0.1 mM; Fig. 5B). After incorporation, CTP and CTP analogs are readily excised via this mechanism. Therefore, the resulting specificity constants indicate that 2'C-Me-CMP is ~1.3-fold more efficiently excised, $K_4 k_5 = (2.0 ± 0.1) \times 10^{-5}$ μM$^{-1}$ s$^{-1}$, whereas 2'C-Me-2'F-CMP is ~1.3-fold less efficiently excised, $K_4 k_5 = (1.2 ± 0.1) \times 10^{-5}$ μM$^{-1}$ s$^{-1}$, compared with CTP.

The specificity constant for the reverse of ATP-mediated excision (reaction of Ap$_4$C; $k_{-2}/K_3 = 0.38 ± 0.2$ μM$^{-1}$ s$^{-1}$) is similar to values previously reported (5). As with the reincorporation of the Ap$_4$C, estimates for the specificity constant for reincorporation of the Ap$_4$C analogs can be obtained from the data. The specificity constant for the reverse of the ATP-mediated excision for 2'C-Me-CMP ($k_{-2}/K_3 = 0.47 ± 0.2$ μM$^{-1}$ s$^{-1}$) is similar to that of Ap$_4$C. For 2'C-Me-2'F-CMP, the efficiency of reincorporation of the dinucleoside is over 2-fold higher compared with Ap$_4$C ($k_{-2}/K_3 = 0.92 ± 0.3$ μM$^{-1}$ s$^{-1}$). This indicates that the modifications play a role in increasing the efficiency of reincorporation of the dinucleoside tetraphosphate after ATP-mediated excision.

ATP-mediated excision of UMP is much less efficient than the excision of CMP and its analogs (Fig. 6B). At the highest ATP concentrations, only ~20% of the input NS5B/10-nt/20-nt complex was excised by the end of the time course, and saturation could not be reached. Therefore, we were only able to estimate the lower limit on the rate constant for excision to calculate the specificity constant from these data. The specificity constant was determined from the ATP concentration dependence of the rate of excision, $(0.05 ± 0.02) \times 10^{-6}$ μM$^{-1}$ s$^{-1}$. This result indicates that, as is the case with pyrophosphorolysis, the efficiency of ATP-mediated excision is greatly reduced with UMP compared with CMP. Moreover, upon attempting to measure ATP-mediated excision of 2'C-Me-2'F-UMP, no excision was observed at any concentration of ATP (Fig. 7B). We set upper limits on the rate constant for ATP-mediated excision of 2'C-Me-2'F-UMP by NS5B by estimating a lower limit for detectable product of <1% turnover by the end of the time course. This lower limit gives an estimated $K_4 k_5 ≤ 0.004 \times 10^{-6}$ μM$^{-1}$ s$^{-1}$.
Therefore, not only does the uracil base lead to resistance to ATP-mediated excision, but also the 2’C modifications further reduce the efficiency of excision. By evading ATP-dependent excision, sofosbuvir provides an effective treatment, whereas mericitabine fails because it is rapidly removed by excision.

Sequence dependence of excision of nucleoside analogs

Previous studies on various polymerases have demonstrated nucleotide incorporation and excision can be influenced by local sequence context (21–24). To survey whether certain sequences are more or less susceptible to incorporation of nucleotide analogues and ATP-mediated excision, a processive elongation assay was performed in the presence of the analogs and a high concentration of ATP. The elongation complex was assembled as indicated under “Materials and methods” using a 45-nt template to generate an NS5B/9-nt/45-nt complex. The 45-nt template was designed to contain multiple opportunities for the analogs to be incorporated. The elongation complex was then mixed with all four NTPs along with a nucleotide analog. The reactions were performed using 50 μM or 3 mM ATP. The results were fit using Scheme 3. According to the template sequence, we expected to see incorporation of the CTP analogs and chain termination at the 11-, 29-, 36-, 40-, and 44-nt positions of the primer strand. Both CTP analogs were efficiently incorporated at each position except for the 29-nt position. This may indicate that there is some sequence dependence for incorporation. Nevertheless, the chain terminators were able to inhibit full extension of the primer strand (Figs. 8A and 9A). By monitoring the reduction in band intensity over time, excision was observed at the 11-nt position of the primer for both CTP analogs at low ATP (Figs. 8B and 9B). The rate constant for excision at the 11-nt position was 0.088 ± 0.01 and 0.028 ± 0.01 s⁻¹ for 2’C-Me-2’F-CTP, respectively. Little excision was observed at the 36-, 40-, and 44-nt positions. This may indicate that efficiency of the excision of the CTP analogs may depend somewhat on local sequence.

For 2’C-Me-2’F-UTP, we expected to observe incorporation at the 10-, 15-, 17-, 18-, 22-, 26-, 28-, 33-, and 43-nt positions of the primer strand. We observed incorporation of the analog, after incorporation of the analog, the curves stay completely flat, indicating that no excision was occurring (Fig. 10). Fitting these results using Scheme 3 yields rate constants for excision that are essentially zero. This demonstrates that the resistance to ATP-mediated excision of the 2’-modified UMP analog appears to be universal and is not dependent on the context of the sequence.

Figure 5. ATP-mediated excision of 2’C-modified CTP analogues. These plots show the ATP-mediated excision of CMP (A), 2’C-Me-CMP (B), and 2’C-Me-2’F-CMP (C). ATP concentrations used were 0.25, 0.5, 1, 2, 4, and 8 μM. The data were fit using Scheme 3 using KinTek Explorer. The solid lines show the best fit generated during the fitting process. Results are summarized in Table 2.

Figure 6. Excision of UTP. The plots show UMP excision by pyrophosphorolysis (250, 500, 1000, and 2000 μM) (A) and ATP-mediated excision (1, 2, 4, and 8 mM) (B). The results were fit to Schemes 2 and 3, respectively, using KinTek Explorer. The solid lines represent the best fit generated during fitting. Results are summarized in Table 2.
Discussion

In this study, we set out to understand the kinetic basis for NS5B inhibition by nucleoside analogs and to assess whether they are able to resist ATP-dependent excision. By isolating an active NS5B elongation complex, we were able to determine the kinetics of incorporation for CTP, UTP, and their respective analogs. NS5B discriminates against incorporation of CTP analogs between 6- and 27-fold with respect to incorporation of the correct substrate. However, there is a 140-fold discrimination against incorporation of the 2'-C-Me-2'F-UTP analog when compared with incorporation of UTP. This result is ~3-fold higher than previously reported (140-fold versus 45-fold (20)). This difference could possibly be explained by the difference in the strains used (Con1 strain versus BK strain). When comparing the differences in discrimination, one would conclude that the 2'-C-modified CTP analogs would be more effective inhibitors. However, 4'-azido-CTP, which showed the lowest discrimination, allowed for slow elongation on top of the azido-CMP and is therefore not an effective chain terminator. Also, it is known from clinical trials that mericitabine, the prodrug that becomes metabolized into 2'-C-Me-2'F-CTP, is less effective at treating HCV infections when compared with sofosbuvir (10, 20). Our data suggest that the effectiveness of the nucleoside analog is not determined by their kinetics of incorporation. Rather, the effectiveness of the nucleoside analog is driven by the ability to resist ATP-dependent excision after incorporation.

Pyrophosphorolysis or ATP-mediated excision reactions could be used to remove chain terminators. In our studies, pyrophosphorolysis occurs more efficiently on the natural CMP base than in the 2'C-Me-CMP analog. The 2'-fluoro modification further decreases the efficiency of pyrophosphorolysis ~2.5-fold, indicating that the 2'C-modifications play a role in mitigating the reversal of analog incorporation. However, our data demonstrate that the efficiency of pyrophosphorolysis depends on the incorporated base. Pyrophosphorolysis of
UMP is ∼245-fold less efficient than that of CMP. Furthermore, our data show that the addition of the 2′C-Me-2′F modification further lowered the efficiency of pyrophosphorolysis to a level undetectable in our assays. Therefore, our data support a model in which the efficiency of pyrophosphorolysis is determined not only by the base, but also by the modifications at the 2′-carbon of the ribose ring.

Pyrophosphorolysis and ATP-mediated excision require that the 3′ end of the RNA primer be in the active site. Following polymerization, the RNA duplex translocates to move the 3′ end out of the active site to allow binding of the next NTP. Thus, translocation will reduce the observed rate of reaction with either ATP or pyrophosphate. It is likely that pyrophosphate (or ATP) will bind only to the untranslocated state. The $K_{d,app}$ for binding pyrophosphate would be attenuated by the equilibrium constant for translocation. Thus, it is likely that the identity of the base and modifications may alter the rate and the equilibrium constant for translocation. Differences in the translocation equilibrium may explain differences in reactivity in comparing CMP and UMP.

The efficiency of pyrophosphorolysis is 15–50-fold higher than ATP-mediated excision for CMP and CMP analogs and 91-fold higher for UMP. However, the average physiological concentrations of pyrophosphate and ATP are ∼3.5 μM and 3 mM, respectively (25, 26). Therefore, ATP-mediated excision will occur at a faster rate than pyrophosphorolysis under physiological conditions (Fig. 11).

ATP-mediated excision by HIV RT plays a significant role in the emergence of AZT resistance (16, 27, 28). Our work has
demonstrated that WT NS5B catalyzes the ATP-mediated excision of CMP 25-fold more efficiently than AZT-resistant variants of HIV RT (14, 16). The addition of the 2'C-Me modification slightly increased the efficiency of ATP-mediated excision compared with CMP, but the addition of the 2'C-Me-2'F modification mitigated the efficiency of ATP-mediated excision. However, ATP-mediated excision of the analogs is significantly higher when compared with the rates of ATP-mediated excision of AZT by resistant mutants of HIV RT (34-fold higher for 2'C-Me-CMP and 20-fold higher for 2'C-Me-2'F-CMP (16). In contrast, ATP-mediated excision of UMP by NS5B is incredibly inefficient. Our results demonstrated that the efficiency is approximately 10-fold lower than AZT excision by HIV RT. The further addition of the 2'C modifications further mitigated the efficiency of ATP-mediated excision to a level undetectable above background. Estimates of the upper limit of the rate constant for ATP-mediated excision of the UMP analog indicate that the efficiency is at least 130-fold lower than AZT excision by resistant HIV RT variants.

Previous studies have demonstrated that a serine to threonine mutation at the 282-position confers resistance to sofosbuvir (29, 30). However, this mutation has not been observed in any clinical isolates. A low frequency of sofosbuvir-resistant mutations emerged during clinical trials (L159F and V321A), which may have contributed to the treatment failing to mitigate the viral infection (31). These mutants required an intensified treatment to achieve sustained virologic response. Our attempts to study the effect of these mutants have been limited due to an...
inability to isolate NS5B variants that can make it through the inefficient de novo initiation to generate an active elongation complex. More work is needed to optimize conditions to determine whether the observed resistance is due to an increase in discrimination against incorporation or an increase in the efficiency of excision reactions.

Our work demonstrates that although 2'C-modified CTP analogs are more efficiently incorporated compared with the UTP analog, the UTP analog is a better inhibitor because of its resistance to ATP-dependent excision. Once the UTP analog is incorporated, it exhibits a resistance to ATP-dependent excision. Once the UTP analog is a better inhibitor because of its resistance to ATP-dependent excision. This resistance is attributed to both the base itself and the additional 2'OH group.

Materials and methods

Nucleic acids and chemicals

CTP and UTP analogs used in this study were generously provided in triphosphate form by Alios BioPharma (now Janssen Pharmaceutical, Inc.) and Gilead Sciences, respectively. The RNA templates, pGG dimer, and OHGG dimer were purchased from Dharmacon, Inc. (Chicago, IL). The sequences of the RNA templates used are shown in Table 4. The OHGG dimer was labeled with [γ-32P]ATP (PerkinElmer Life Sciences) using T4 polynucleotide kinase from New England Biolabs (Ipswich, MA) according to the protocol recommended by New England Biolabs. The reaction was stopped by incubating at 95°C for 3 min. The radiolabeled pGG was diluted 10-fold with cold pGG to make a radiolabeled stock solution of a known concentration. Ribonucleoside triphosphates were purchased from Promega (Madison, WI). Tris-HCl buffers, NaCl, MgCl2, and EDTA solutions were purchased from Ambion (Austin, TX). Octyl β-D-glucopyranoside and DTT were purchased from GoldBio (St. Louis, MO).

Expression and purification of NS5BΔ21

N-terminal hexa-His-NS5BΔ21 (Con1 strain, GT1b with the C-terminal 21-amino acid membrane anchor domain deleted) was cloned into a pC(pc(, inducible) vector (32) under control of a rightward promoter from bacteriophage λ controlled by a chemically inducible and temperature-inducible λ repressor encoded on the plasmid. Plasmids were transformed into New England Biolabs Turbo Escherichia coli cells and cultured in Terrific Broth at 30°C overnight. One liter of medium was inoculated with the cultures grown overnight at an A600 of 0.1 and grown at 30°C until an A600 of 4 was reached. Expression was induced by the addition of nalidixic acid to a final concentration of 50 μg/ml, and the temperature was raised to 37°C. After 16 h, cells were collected, and the pellets were stored at −80°C. Cells were resuspended in lysis buffer (50 mM HEPES, pH 7.5, 300 mM NaCl, 2 mM DTT, 20% (v/v) glycerol, 0.1% (w/v) octyl β-D-glucopyranoside, 20 mM imidazole, Pierce EDTA-free protease inhibitor tablets (Thermo Fisher Scientific)) and incubated with 300 μg/ml lysozyme on ice for 20 min. The lysate was sonicated for 20 min on ice using a Branson Sonifier 450 (duty cycle = 20%, output = 5) and then centrifuged at 105,000 × g for 30 min at 4°C using a Beckman Optima LE-80K Ultracentrifuge. The supernatant was loaded onto a 5-ml HisTrap HP column (GE Healthcare) equilibrated in lysis buffer. NS5BΔ21 was eluted using a gradient of 0–100% elution buffer (50 mM HEPES, pH 7.5, 300 mM NaCl, 2 mM DTT, 20% (v/v) glycerol, 0.1% (w/v) octyl β-D-glucopyranoside, 400 mM imidazole) over 10 column volumes. Peak fractions were pooled, concentrated, and dialyzed into storage buffer (30 mM Tris-HCl, pH 7.5, 400 mM NaCl, 5 mM DTT, 20% (v/v) glycerol, and 0.1% (w/v) octyl β-D-glucopyranoside). The concentration was determined by measuring the absorbance at 280 nm using an extinction coefficient of 170,850 cm⁻¹ M⁻¹ (5). The protein was stored at −80°C until use.

Assembly and isolation of elongation complex

A reaction containing 12 μM NS5B, radiolabeled 20 μM pGG, 20 μM RNA template was incubated at 30°C for 1.5 h to form an elongation complex of NS5B with a 9-nt primer and a 20- or 45-nt template (NS5B/9-nt/20-nt or 45-nt). For the 20-nt CG template 50 μM ATP and UTP were added. For the 20-nt UA and 45-nt templates 50 μM ATP and GTP were added. Reactions were carried out in buffer containing 40 mM Tris-HCl, pH 7.0, 40 mM NaCl, 5 mM DTT, and 2 mM MgCl2. The elongation complex was isolated by centrifuging at 16,000 rpm for 5 min using a benchtop centrifuge. The supernatant was discarded, and the pellet was washed twice with wash buffer (40 mM Tris-

Table 4

RNA templates

The underlined base indicates the last template position before the reaction pauses during elongation complex assembly. The base in red indicates the templating base for the next incorporation.

<table>
<thead>
<tr>
<th>Template</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>20-nt CG</td>
<td>3'-CCUAUUUUAGCAUUAUCUA-5'</td>
</tr>
<tr>
<td>20-nt UA</td>
<td>3'-CCUCUCUCUAAGCAUUAUCUA-5'</td>
</tr>
<tr>
<td>45-nt</td>
<td>3'-CCUCUCUCAAUGCAUUAUCUACAGUUCACC-GUUCGCCAGU-5'</td>
</tr>
</tbody>
</table>

Figure 12. Half-life of incorporated nucleotides. The chart shows the t½ of each incorporated nucleotide and analog due to ATP-mediated excision. t½ was calculated using the equation, t½ = ln(2)/k, where k is the rate of ATP-mediated excision at physiological concentrations of ATP (Fig. 11).
HCl, pH 7.0, 20 mM NaCl, 5 mM DTT, and 2 mM MgCl₂) to remove contaminants. The pellet was resuspended in a buffer containing 40 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM DTT, and 2 mM MgCl₂.

**Assembly and isolation of NS5B/10-nt/20-nt elongation complex**

The reaction described above was performed to generate the NS5B/9-nt/45-nt elongation complex followed by the addition of 20 μM next correct NTP or 100 μM nucleoside analog. The reaction was incubated at 30 °C for 20 s for NTP incorporation or 5 min for nucleoside analog incorporation to generate the NS5B/10-nt/20-nt elongation complex. The elongation complex was pelleted, washed twice, and resuspended as described above.

**Measurement of incorporation of nucleoside triphosphate and nucleoside analogs**

The elongation complex was assembled, washed, and resuspended in a buffer containing 40 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM DTT, and 2 mM MgCl₂. To measure the kinetics of NTP incorporation, resuspended elongation complex was rapidly mixed with an equal volume of solution containing NTP in the same buffer using a rapid-quench-flow instrument (KinTek Corp., Austin, TX). Reactions were quenched in a solution containing 50 mM EDTA and collected and stored in solution containing 50 mM EDTA, 90% formamide, 0.1% bromphenol blue, and 0.1% xylene cyanol FF. The samples were heat-denatured by incubating at 95 °C for 5 min and loaded onto a 16% denaturing polyacrylamide gel containing 7M urea. Electrophoresis, drying, exposure, and quantification were conducted as described in previous sections. The concentrations of each nt position over time were plotted versus time in Microsoft Excel.

**Pyrophosphorolysis and ATP-mediated excision**

The NS5B/10-nt/20-nt elongation complex was generated, pelleted, and resuspended in buffer as described above. The elongation complex was mixed with an equal volume of solution containing 50 μM CTP, GTP, UTP, and ATP, and either 500 μM 2′-modified CTP analog or 1 mM 2′F-2′CMe-UTP in the same buffer and allowed to react at 30 °C. To test for ATP-mediated excision, the elongation complex was generated, pelleted, and resuspended in buffer as described previously. It was then mixed with an equal volume of solution containing 50 μM CTP, GTP, and UTP, 3 mM ATP and either 500 μM 2′-modified CTP analog or 1 mM 2′F-2′CMe-UTP in the same buffer and allowed to react at 30 °C. For each given time point, an aliquot was removed from the reaction and quenched in a solution containing 50 mM EDTA, 90% formamide, 0.1% bromphenol blue, and 0.1% xylene cyanol FF. The samples were heat-denatured and loaded onto a 16% denaturing polyacrylamide gel with 7 M urea. Electrophoresis, drying, exposure, and quantification were conducted as described previously.

**Data analysis**

The kinetics of incorporation, pyrophosphorolysis, and ATP-mediated excision were fit using KinTek Explorer (KinTek Corp.) to determine the rate constants of the respective reactions as described previously (19, 33). The kinetics of incorporation were determined by fitting using Scheme 1. To fit the data to determine the $K_{\text{d,app}}$ for NTP binding, the rate constant for NTP or nucleotide analog binding ($k_1$) was assumed to be close to diffusion-limited and locked at 100 μM⁻¹s⁻¹, and the rate constant for dissociation ($k_{-1}$) was allowed to vary during fitting. The apparent equilibrium dissociation constant was then calculated by dividing the rate constant for dissociation by the rate constant for binding ($\frac{k_{d,\text{app}}}{k_1} = \frac{k_{-1}}{k_1}$). The maximum rate constant for polymerization ($k_{\text{pol}}$) afforded definition of the rate constant $k_2$. Because the amount of pyrophosphate produced during the reaction is low relative to nucleotide, the reaction is largely irreversible; therefore, $k_{-2}$ was locked at 0. Pyrophosphate release is fast and not rate-limiting, so the $k_3$ is locked at 100 s⁻¹. The specificity constant ($\frac{k_{\text{cat}}}{K_m} = k_{\text{pol}}/K_{d,\text{app}}$) was determined by dividing the rate constant for polymerization by the $K_{d,\text{app}}$ for nucleotide binding ($\frac{k_{\text{cat}}}{K_m} = K_{d,\text{app}}/k_2$).

The kinetics of pyrophosphorolysis were determined by fitting using the reverse reactions shown in Scheme 1. Pyrophosphorolysis reactions were globally fit, including incorporation reactions, to account for the amplitude dependence observed. The rate constant for pyrophosphate binding ($k_{-3}$) was assumed to be diffusion-limited and locked at 100 μM⁻¹s⁻¹. The rate constants for pyrophosphate dissociation ($k_3$) and pyrophosphorolysis ($k_{-2}$) were allowed to vary during fitting. The $K_{d,\text{app}}$ for pyrophosphate was determined by dividing the rate constant for pyrophosphate release by the rate constant for binding ($\frac{K_{d,\text{app}}}{K_m} = k_3/k_{-3}$). The specificity constant for pyrophosphorolysis ($\frac{k_{\text{cat}}}{K_m}$) was determined by dividing the
rate constant for pyrophosphorolysis by the $K_{d,\text{app}}$ for pyrophosphate binding ($k_{-2}/K_3$).

The kinetics of ATP-mediated excision were determined by fitting using Scheme 2. To determine the apparent equilibrium dissociation constant for ATP ($K_{d,\text{app}}$), the rate constant for ATP binding ($k_4$) was assumed to be diffusion-limited and locked at $100 \text{ mM}^{-1} \text{s}^{-1}$. The rate constant for ATP dissociation ($k_{-4}$) was allowed to vary during the fitting process. The rate constant for the dissociation of ATP was then divided by the rate constant for binding to determine the $K_{d,\text{app}}$ ($1/K_4 = k_{-4}/k_4$). The maximum rate constant for ATP-mediated excision was determined by allowing $k_5$ to vary during the fitting process. The specificity constant was determined by multiplying $k_5$ by $1/K_{d,\text{app}} (k_{\text{cat}}/K_m = K_5 k_6)$. The rates for the reverse of ATP-mediated excision ($k_{-5}$) and Ap4N release ($k_6$) were linked at a constant ratio during fitting. Due to the low concentration of Ap4N, the rate constant for Ap4N rebinding ($k_{-6}$) was assumed to be slow and locked at $1 \text{ mM}^{-1} \text{s}^{-1}$.

For the processive elongation in the presence of nucleotide analog, the concentration of each chain-terminated primer position was plotted versus time in KinTek Explorer. The curves for each primer position were fit by simulation using the processive elongation model in Scheme 3. This model accounts for NTP incorporation ($E.R_n \rightarrow E.R_{n+1}$), chain termination due to nucleotide analog incorporation ($E.R_n \rightarrow E.R_5$), and possible ATP-mediated excision leading to RNA synthesis rescue ($E.R_X \rightarrow E.R_n$. Ap4NA $\rightarrow E.R_n$).

Acknowledgments—2‘C-Me-CTP, 2‘C-Me-2’F-CTP, and 4’-azido-CTP were provided by Janssen Pharmaceutical, Inc. 2‘C-Me-2’F-UTP was provided by Gilead Sciences.

Author contributions—B. V. and J. L. conceptualization; B. V. and J. L. data curation; B. V. and J. L. formal analysis; B. V. and J. L. investigation; B. V. writing-original draft; K. A. J. resources; K. A. J. supervision; K. A. J. validation; K. A. J. project administration; K. A. J. writing-review and editing.

Funding and additional information—This work was supported by grants from NIAID, National Institutes of Health, Grant 1R01AI110577 (to K. A. J.) and Welch Foundation Grant F-1604 (to K. A. J.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of interest—K. A. J. is president of KinTek Corporation, which provided the RQF-3 rapid quench-flow instrument and KinTek Explorer software used in this study.

Abbreviations—The abbreviations used are: HCV, hepatitis C virus; NS5B, nonstructural protein 5B; nt, nucleotide; Ap4N, adenine dinucleoside tetraphosphate; AZT, azidothymidine.

References


